Table 1.
Relative Effect Tables for MACE and Clinically Significant Bleeding End Points From Fixed Effect Model Analysis
| Apixaban+SAPT |
Dabigatran 110 mg+SAPT |
Dabigatran 150 mg+SAPT |
Edoxaban+SAPT | Rivaroxaban+SAPT | VKA+DAPT | ||
|---|---|---|---|---|---|---|---|
| MACE | Apixaban+SAPT | … |
1.05 (0.7, 1.58) |
0.81 (0.53, 1.24) |
0.98 (0.58, 1.66) |
0.94 (0.55, 1.59) |
0.92 (0.66, 1.29) |
|
Dabigatran 110 mg+SAPT |
0.95 (0.63, 1.43) |
… |
0.78 (0.6, 1) |
0.93 (0.59, 1.48) |
0.89 (0.56, 1.44) |
0.88 (0.7, 1.11) |
|
|
Dabigatran 150 mg+SAPT |
1.23 (0.8, 1.89) |
1.29 (1, 1.68) |
… |
1.2 (0.74, 1.96) |
1.15 (0.71, 1.89) |
1.14 (0.87, 1.49) |
|
| Edoxaban+SAPT |
1.03 (0.6, 1.73) |
1.07 (0.67, 1.71) |
0.83 (0.51, 1.35) |
… |
0.96 (0.54, 1.7) |
0.95 (0.63, 1.41) |
|
| Rivaroxaban+SAPT |
1.07 (0.63, 1.82) |
1.12 (0.7, 1.8) |
0.87 (0.53, 1.42) |
1.04 (0.59, 1.86) |
… |
0.99 (0.65, 1.49) |
|
| VKA+DAPT |
1.08 (0.77, 1.51) |
1.13 (0.9, 1.44) |
0.88 (0.67, 1.15) |
1.06 (0.71, 1.58) |
1.01 (0.67, 1.53) |
… | |
| Clinically significant bleeding | Apixaban+SAPT | … |
1.68 (1.22, 2.32) |
2.2 (1.6, 3.04) |
2.38 (1.69, 3.38) |
1.84 (1.3, 2.61) |
2.92 (2.29, 3.78) |
|
Dabigatran 110 mg+SAPT |
0.6 (0.43, 0.82) |
… |
1.31 (1.05, 1.65) |
1.42 (1.04, 1.95) |
1.1 (0.8, 1.5) |
1.75 (1.43, 2.14) |
|
|
Dabigatran 150 mg+SAPT |
0.46 (0.33, 0.62) |
0.76 (0.61, 0.95) |
… |
1.08 (0.79, 1.48) |
0.84 (0.61, 1.14) |
1.33 (1.09, 1.62) |
|
| Edoxaban+SAPT |
0.42 (0.3, 0.59) |
0.7 (0.51, 0.96) |
0.92 (0.68, 1.26) |
… |
0.77 (0.55, 1.09) |
1.23 (0.96, 1.57) |
|
| Rivaroxaban+SAPT |
0.54 (0.38, 0.77) |
0.91 (0.67, 1.25) |
1.2 (0.88, 1.64) |
1.29 (0.92, 1.83) |
… |
1.59 (1.25, 2.03) |
|
| VKA+DAPT |
0.34 (0.26, 0.44) |
0.57 (0.47, 0.7) |
0.75 (0.62, 0.91) |
0.81 (0.64, 1.04) |
0.63 (0.49, 0.8) |
… |
DAPT indicates dual antiplatelet therapy; MACE, major adverse clinical event; SAPT, single antiplatelet therapy; VKA, vitamin K antagonist.